Institutions, not individuals, carried the Paras Healthcare IPO subscription. When the book closed on 23 October 2026, qualified institutional buyers had bid 3.25 times their quota, retail investors 2.10 times and non-institutional investors only 0.69 times, giving 2.34 times overall for the Rs 1,450 crore hospital issue. The shares are expected to list on BSE and NSE on 28 October. Figures are as reported at about 5:00 PM IST and may be revised.
Key takeaways: who drove the Paras Healthcare IPO subscription
- Overall subscription: 2.34 times, after 0.15 times on day one and 0.36 times on day two.
- Qualified institutional buyers (ex-anchor): 3.25 times.
- Retail individuals: 2.10 times.
- Non-institutional investors: 0.69 times (small NIIs 0.84 times, big NIIs 0.62 times).
- Allotment on 26 October, refunds and credit on 27 October, tentative listing on 28 October.
Reading the Paras Healthcare IPO subscription by investor category
Indian public issues divide the offer into quotas for institutions, non-institutional investors (often wealthy individuals and firms) and retail investors. Each is subscribed separately, so the headline number blends very different behaviours. Here, the institutional quota was comfortably covered, the retail quota roughly doubled, and the non-institutional quota was not fully covered.
The gap between big NIIs at 0.62 times and small NIIs at 0.84 times is also visible. Large investors who often borrow to bid or who bid late can be sensitive to expected listing gains, so a weak showing there is sometimes read as caution. That reading is ours, not a finding of the exchange data, and the sources do not explain it.
Day-wise path of the Paras Healthcare IPO subscription
- Day one: 0.15 times.
- Day two: 0.36 times.
- Day three (close, 23 October): 2.34 times.
Bids totalled about 2,69,43,378 shares, or roughly Rs 1,867 crore at the Rs 693 upper band according to one tally. Against the portion open after the anchor allocation, which we calculate at about 1.15 crore shares, that is consistent with the 2.34 times figure. Sources differ slightly on timing, with one citing 5:55 PM, and final numbers can move after reconciliation.
The structure of the Paras Healthcare IPO subscription
The issue combines a fresh issue of Rs 500 crore (72,15,007 shares) and an offer for sale of Rs 950 crore (1,37,08,513 shares), so about two-thirds, by our calculation, is existing shareholders selling. Price band: Rs 660 to Rs 693; face value Re 1; lot size 21 shares, or Rs 14,553 at the upper band. The anchor portion was 94,15,584 shares, 45% of the net issue, and the sources give no investor names. JM Financial manages the issue and MUFG Intime India is the registrar. Offer documents are filed with SEBI.
Valuation: what the Paras Healthcare IPO subscription is paying for
At the upper band the post-issue market capitalisation is about Rs 7,498 crore, according to our earlier coverage. Set against FY26 profit of Rs 43.83 crore, that implies roughly 170 times trailing earnings, our own calculation. Revenue was Rs 1,605.95 crore in FY26 against Rs 1,294.06 crore in FY25, and the company swung from a loss of Rs 57.98 crore to a profit. See our earlier report for the offer details.
A very high trailing multiple is common for companies just turning profitable, but it leaves little room for disappointment. Whether institutions are looking at forward earnings, bed expansion or asset value, the announcements do not say.
How the Paras Healthcare IPO subscription compares with the hospital sector backdrop
The company runs eight hospitals with 2,211 beds and aims for 3,011 beds by March 2028, as disclosed in the offer details we reported. India’s listed hospital chains have been valued on bed growth and occupancy. We did not compile peer multiples for this article, so we make no claim on whether the pricing is high or low relative to peers.
Questions about allotment after the Paras Healthcare IPO subscription
With retail demand at 2.10 times, on average about half of retail demand cannot be met in full, which is our own simple calculation. Allotment is usually decided by lottery in lots of the minimum bid, and the exact retail allotment ratio has not been published in the sources we saw. Institutional bidders are allotted proportionately. Applicants who do not receive shares should see refunds from 27 October. Those who receive shares can sell from the listing day. These are general features of the process, not forecasts for this issue.
Listing-day timeline
- 26 October: basis of allotment.
- 27 October: refunds and demat credit.
- 28 October: tentative listing. Notices appear on nseindia.com and bseindia.com.
Our analysis of the Paras Healthcare IPO subscription
In our assessment, the Paras Healthcare IPO subscription is a mixed signal: strong institutional appetite, moderate retail interest and weak interest from large non-institutional investors. That pattern is often associated with a cautious but not hostile market, though we cannot verify motives. Because the issue is two-thirds sale by existing holders, proceeds to the company are limited to the Rs 500 crore fresh component.
We make no listing prediction, and this is not investment advice.
What is not disclosed
- Anchor investor names and amounts.
- Final reconciled subscription.
- Retail allotment ratio.
- Use of proceeds in detail.
Risks and caveats
Subscription levels are not predictors of listing prices. Numbers are a snapshot and sources vary on the closing time. We found no Acumen Research and Consulting report that covers Indian hospital IPOs, so no Acumen statistics are cited. This is news reporting and not investment advice.
What to watch next
- Final subscription data.
- Allotment status and refunds.
- Debut trading on 28 October.
- Whether institutional holders in the anchor book are disclosed.
FAQ
Which category was most subscribed in the Paras Healthcare IPO subscription?
Qualified institutional buyers, at 3.25 times.
Was the non-institutional portion fully subscribed?
No. It was subscribed 0.69 times.
When will the shares list?
Tentatively on 28 October 2026 on BSE and NSE.
How we reported this: we relied on exchange-linked subscription data and company issue details as reported, our own earlier coverage and the regulator and exchange sites linked above. Where figures are our calculations, we say so. Last updated 24 October 2026. This is news reporting and not advice.
